News
KZIA
12.43
+1.35%
0.17
Weekly Report: what happened at KZIA last week (0720-0724)?
Weekly Report · 9h ago
Weekly Report: what happened at KZIA last week (0713-0717)?
Weekly Report · 07/20 09:07
Buy Rating Reaffirmed on Kazia as Paxalisib Prospects Strengthen; $30 Price Target Maintained
TipRanks · 07/16 16:55
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)
TipRanks · 07/16 10:40
Kazia Therapeutics Price Target Maintained With a $34.00/Share by BTIG
Dow Jones · 07/15 17:30
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target
Benzinga · 07/15 17:20
Weekly Report: what happened at KZIA last week (0706-0710)?
Weekly Report · 07/13 09:08
Weekly Report: what happened at KZIA last week (0629-0703)?
Weekly Report · 07/06 09:08
Kazia Therapeutics Price Target Announced at $34.00/Share by BTIG
Dow Jones · 07/01 11:46
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
Benzinga · 07/01 11:36
Kazia Therapeutics initiated with a Buy at BTIG
TipRanks · 07/01 10:41
Weekly Report: what happened at KZIA last week (0622-0626)?
Weekly Report · 06/29 09:07
Weekly Report: what happened at KZIA last week (0615-0619)?
Weekly Report · 06/22 09:09
Kazia Therapeutics CFO James Levine files initial beneficial ownership statement
PUBT · 06/15 22:53
Weekly Report: what happened at KZIA last week (0608-0612)?
Weekly Report · 06/15 09:08
ADRs Advance; 111 Inc. Climbs 14%
Dow Jones · 06/12 20:30
Kazia Therapeutics Price Target Announced at $32.00/Share by Lake Street
Dow Jones · 06/11 15:02
Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32
Benzinga · 06/11 14:53
Kazia Therapeutics initiated with a Buy at Lake Street
TipRanks · 06/11 11:46
Weekly Report: what happened at KZIA last week (0601-0605)?
Weekly Report · 06/08 09:08
More
Webull provides a variety of real-time KZIA stock news. You can receive the latest news about Kazia Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.